journal article·2026-07-20Open access

A Programmable Calcification Nanoplatform for Loco‐Regional Calcification‐Immune Hepatocellular Carcinoma Therapy

Long Liu, Peng Li, Zhixiang Lu, Shuqin Xu, Juanjuan Wang, Kai Ma, Haodong Yu, Can Zhou, Hu Chen, Gang Liu, Yi Lyu, Shuang Bai

Abstract

ABSTRACT Inducing tumor calcification is a promising strategy for disrupting cancer progression, yet achieving efficient biomineralization with synergistic antitumor effects remains challenging. Here, a programmable calcification nanoplatform (CaIM) is developed using in situ growth of calcium peroxide (CaO 2 ) on black phosphorus (BP) nanosheets, followed by hyaluronic acid encapsulation. Unlike conventional physical adsorption or co‐precipitation, this in situ growth strategy yields crystalline CaO 2 uniformly anchored on the BP matrix, enabling synchronized release of Ca 2 + , phosphate, and H 2 O 2 in the tumor microenvironment. CaIM induces potent intracellular calcium overload and oxidative stress, triggering mitochondrial dysfunction, cell death, and extensive biological calcification readily visualized via computed tomography (CT). Multi‐omics profiling identifies the mucolipin channel MCOLN2 as a key mediator regulating calcium flux, facilitating stable active biomineralization rather than passive necrotic calcification. This active calcification, coupled with mitochondrial damage, effectively reshapes the immunosuppressive microenvironment by promoting macrophage polarization and T cell infiltration. These findings establish a calcium signaling‐driven paradigm integrating nanocomposite design with synergistic calcium stress, oxidative damage, and immune activation, offering a robust foundation for calcification‐based cancer therapy.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Parathyroid Disorders and Treatments · Cancer, Hypoxia, and Metabolism

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Shaanxi Province Center for Regenerative Medicine and Surgery Engineering Research The First Affiliated Hospital of Xi'an Jiaotong University Xi'an China

National Local Joint Engineering Research Center for Precision Surgery & Regenerative Medicine The First Affiliated Hospital of Xi'an Jiaotong University Xi'an China

Department of Hepatobiliary Surgery The First Affiliated Hospital of Xi'an Jiaotong University Xi'an China

Institute of Regenerative and Reconstructive Medicine Med‐X Institute The First Affiliated Hospital of Xi'an Jiaotong University Xi'an China

State Key Laboratory of Cellular Stress Biology Innovation Center for Cell Biology School of Life Sciences Xiamen University Xiamen China

Department of Breast Surgery The First Affiliated Hospital of Xi'an Jiaotong University Xi'an China

Funding

National Natural Science Foundation of China · Major State Basic Research Development Program of China · Fundamental Research Funds for the Central Universities

References (47)

Show source-provided references
1. 10.1002/anie.20201612210.1002/anie.202016122 ↗
2. 10.1007/s40820‐022‐00894‐610.1007/s40820‐022‐00894‐6 ↗
3. 10.21873/anticanres.1441910.21873/anticanres.14419 ↗
4. 10.1016/j.biomaterials.2024.12294410.1016/j.biomaterials.2024.122944 ↗
5. 10.1002/advs.20250067010.1002/advs.202500670 ↗
6. 10.7150/thno.9993110.7150/thno.99931 ↗
7. 10.1038/s41467‐024‐54402‐y10.1038/s41467‐024‐54402‐y ↗
8. 10.1002/advs.20241255310.1002/advs.202412553 ↗
9. 10.1126/sciadv.adu951210.1126/sciadv.adu9512 ↗
10. 10.1016/j.tplants.2022.11.00110.1016/j.tplants.2022.11.001 ↗
11. 10.1186/s12967‐025‐06912‐610.1186/s12967‐025‐06912‐6 ↗
12. 10.1002/anie.20231757810.1002/anie.202317578 ↗
13. 10.7150/thno.11162510.7150/thno.111625 ↗
14. 10.1002/cam4.668210.1002/cam4.6682 ↗
15. 10.1038/s41565‐025‐02022‐y10.1038/s41565‐025‐02022‐y ↗
16. 10.1038/s41565‐022‐01125‐010.1038/s41565‐022‐01125‐0 ↗
17. 10.1038/3503603510.1038/35036035 ↗
18. 10.1101/cshperspect.a03880210.1101/cshperspect.a038802 ↗
19. 10.1038/s41580‐018‐0052‐810.1038/s41580‐018‐0052‐8 ↗
20. 10.1016/j.ceca.2017.08.00810.1016/j.ceca.2017.08.008 ↗
21. 10.1016/j.redox.2015.08.01010.1016/j.redox.2015.08.010 ↗
22. 10.1038/s41392‐025‐02253‐410.1038/s41392‐025‐02253‐4 ↗
23. 10.1016/j.mtbio.2025.10164910.1016/j.mtbio.2025.101649 ↗
24. 10.1021/acsnano.1c0276510.1021/acsnano.1c02765 ↗
25. Chloroquine Modulates Antitumor Immune Response by Resetting Tumor‐Associated Macrophages Toward M1 Phenotype10.1038/s41467-018-03225-9 ↗
26. 10.1097/CAD.000000000000072610.1097/CAD.0000000000000726 ↗
27. 10.1039/D4CS00007B10.1039/D4CS00007B ↗
28. 10.1038/ncomms1296710.1038/ncomms12967 ↗
29. 10.1186/s10020‐024‐00858‐z10.1186/s10020‐024‐00858‐z ↗
30. 10.1007/s12975‐021‐00912‐610.1007/s12975‐021‐00912‐6 ↗
31. 10.7150/thno.10781210.7150/thno.107812 ↗
32. 10.1152/physrev.00044.202310.1152/physrev.00044.2023 ↗
33. 10.3390/biom1503038110.3390/biom15030381 ↗
34. 10.7150/thno.6571610.7150/thno.65716 ↗
35. 10.1007/s00204‐025‐04160‐710.1007/s00204‐025‐04160‐7 ↗
36. 10.1016/j.tcb.2022.07.00410.1016/j.tcb.2022.07.004 ↗
37. 10.1016/j.semcancer.2019.12.00610.1016/j.semcancer.2019.12.006 ↗
38. Amplifying Ca2+ Overload by Engineered Biomaterials for Synergistic Cancer Therapy10.1016/j.biomaterials.2024.123027 ↗
39. 10.1016/j.biomaterials.2021.12098710.1016/j.biomaterials.2021.120987 ↗
40. 10.1186/s12951‐021‐01055‐410.1186/s12951‐021‐01055‐4 ↗
41. 10.1016/j.actbio.2024.12.01010.1016/j.actbio.2024.12.010 ↗
42. 10.1016/j.redox.2025.10396110.1016/j.redox.2025.103961 ↗
43. 10.1002/adhm.20240157410.1002/adhm.202401574 ↗
44. 10.3390/ijms2201012010.3390/ijms22010120 ↗
45. 10.2217/fon‐2021‐142210.2217/fon‐2021‐1422 ↗
46. 10.1016/j.ejmech.2020.11296610.1016/j.ejmech.2020.112966 ↗
47. 10.1016/j.biopha.2024.11674010.1016/j.biopha.2024.116740 ↗